These studies provide evidence that NLRP3 inflammasome inhibitors can function as potential novel therapeutic agents for human inflammatory bowel disease and, considering the correlation between the NLRP3 inflammasome and cancer, suggest new avenues for CAC treatment. Here, NLRP3 is linked to inflammatory bowel disease.